Airway Medix S.A. 任命新任监事会成员，并为即将召开的临时股东大会提名两位候选人

Warsaw, May 11, 2026: Airway Medix S.A. (WSE: AWM), a MedTech company listed on the Warsaw Stock Exchange, announces the appointment of Dr. Matthias Kuss to its Supervisory Board, as well as the nomination of Mr. Christophe Geisert and Mr. Julius Brandt as candidates for Supervisory Board membership, subject to approval at the upcoming Extraordinary General Assembly. Together, they bring complementary expertise spanning international healthcare management, medical device engineering, and regulatory affairs, areas relevant to the Company's current stage of development.

Dr. Matthias Kuss: Healthcare Management and Digital Health

Dr. Matthias Kuss is an experienced international executive with a career spanning healthcare, MedTech, innovation, digital transformation, and strategic development. He has held senior leadership roles at Fresenius Medical Care, Allianz Partners, and Carl Zeiss AG, where he combined strategic oversight with operational execution across technologically enabled healthcare, portfolio development, innovation initiatives, and business transformation.

His professional profile brings together experience in corporate strategy, digital health, data-driven healthcare solutions, and the development of scalable business models in regulated environments. In addition to his corporate roles, he has been involved in entrepreneurial healthcare initiatives including telehealth and digital care solutions.

Dr. Kuss holds a PhD in Business and Management from ETH Zurich and a degree in physics. This combination of business and technical education complements his international management experience.

"Joining Airway Medix's Supervisory Board is an opportunity to contribute to a company operating in an important area of healthcare innovation," said Matthias Kuss. "I believe that disciplined execution, strong partnerships, and a clear strategic perspective are essential in building and developing innovative healthcare businesses. I look forward to supporting Airway Medix with my experience in healthcare, digital transformation, and international business development."

Mr. Christophe Geisert, Dipl.-Ing.: Medical Device Engineering and R&D (Candidate for Supervisory Board)

Mr. Christophe Geisert is a results-driven executive with extensive hands-on experience in medical device engineering, product development, and R&D leadership. Over the course of his career, he has held senior positions including Vice President of R&D at international orthopedic and spine device companies operating across the United States and France: Olympus Biotech International (France) and Olympus Biotech Corp. (USA), as well as founder and CEO of his own biomedical engineering consulting firm Lizard-Innovation in Germany.

With over 90 patents and deep expertise in orthopedic, spine, and biomechanical devices, Mr. Geisert has led multidisciplinary engineering teams through the complete product development lifecycle, from early-stage concept through to regulatory submission, clinical studies, and commercialization. His experience encompasses medical device design, ISO 13485 quality management, risk management frameworks, and the integration of biologics with medical device technologies.

Mr. Geisert holds a degree in Medical and Biomedical Engineering (Diplom-Ingenieur, FH), and his background combines strong technical depth with commercial and business development experience in the global medical device sector.

Mr. Julius Brandt, M.Sc., RAC: Regulatory Affairs and Quality Management (Candidate for Supervisory Board)

Mr. Julius Brandt is an experienced Regulatory Affairs and Quality Management professional with over ten years of experience in the global medical device industry. He holds the RAC-Devices certification and has deep expertise in EU MDR, FDA QSR, and MDSAP regulatory frameworks.

In his most recent role, Mr. Brandt served as Director of Corporate Quality and Regulatory Product Lifecycle Management at Karl Storz SE & Co., where he was responsible for global compliance across all product portfolios (Surgical Imaging, Devices, Instruments, and Digital OR, including Software, AI and Robotics) and led an international team of over 40 quality and regulatory professionals. Prior to this, he held Director-level positions in Regulatory Intelligence and Regulatory Affairs, with a track record of leading complex regulatory transitions, including MDR portfolio compliance, and implementing regulatory information management systems.

Mr. Brandt brings a practical, hands-on approach to regulatory strategy combined with experience in managing cross-functional teams across international locations.

Board Composition and Governance: The appointment of Dr. Kuss and the nominations of Mr. Geisert and Mr. Brandt are a direct expression of the Company's precisely planned development strategy and its advancing commercialization agenda. The new Supervisory Board member, and the two candidates if approved by the Extraordinary General Assembly, will strengthen the governance framework with competencies in international sales, distribution, regulatory navigation, and the commercialization of innovative MedTech devices, consistent with the Company's established development plan and its deepening European partnerships. Full details of the appointment and nominations are available in the current ESPI reports published by the Company on the Warsaw Stock Exchange information system.

About Airway Medix S.A.: Airway Medix S.A. focuses on the research, development and commercialization of innovative disposable devices for mechanically ventilated patients in Intensive Care Units (ICUs), as well as life-threatening patients and anesthesiology departments. The products offered by Airway Medix address the most pressing clinical needs and fill a gap in current medical devices. Airway Medix S.A. has been listed on the Warsaw Stock Exchange since 2014.